Lazabemide

Lazabemide
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name N-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide;
CAS Number	103878-84-8;
PubChem CID	71307;
IUPHAR/BPS	6640;
ChemSpider	64426;
UNII	420HD787N9;
KEGG	D04681;
CompTox Dashboard (EPA)	DTXSID2048294 ;
Chemical and physical data
Formula	C8H10ClN3O
Molar mass	199.64 g·mol−1

Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.^[1]

References

^ Henriot S, Kuhn C, Kettler R, Da Prada M (1994). "Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings". J Neural Transm Suppl. 41: 321–325. doi:10.1007/978-3-7091-9324-2_42. ISBN 978-3-211-82521-1. PMID 7931245.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.